Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
Phathom Pharmaceuticals (NASDAQ: PHAT) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, at 8:00 am EDT. The company will host a live webcast accessible through their investor relations website, with a recording available for 90 days afterward.
Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan) tablets in the United States. Their product lineup includes treatments for:
- Non-Erosive GERD heartburn relief in adults
- Healing and maintenance of Erosive GERD in adults
- H. pylori infection treatment through VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®
Phathom Pharmaceuticals (NASDAQ: PHAT) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per giovedì 1 maggio 2025, alle 8:00 EDT. La società trasmetterà un webcast in diretta accessibile tramite il sito web per gli investitori, con la registrazione disponibile per 90 giorni successivi.
Phathom è specializzata nei trattamenti per le malattie gastrointestinali e commercializza negli Stati Uniti le compresse VOQUEZNA® (vonoprazan). La loro gamma di prodotti comprende trattamenti per:
- Sollievo dal bruciore di stomaco da GERD non erosiva negli adulti
- Guarigione e mantenimento della GERD erosiva negli adulti
- Trattamento dell'infezione da H. pylori tramite VOQUEZNA® TRIPLE PAK® e VOQUEZNA® DUAL PAK®
Phathom Pharmaceuticals (NASDAQ: PHAT) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización comercial para el jueves 1 de mayo de 2025 a las 8:00 am EDT. La compañía realizará una transmisión en vivo accesible a través de su sitio web para inversores, con una grabación disponible durante 90 días después.
Phathom se especializa en tratamientos para enfermedades gastrointestinales y comercializa en Estados Unidos las tabletas VOQUEZNA® (vonoprazan). Su línea de productos incluye tratamientos para:
- Alivio de la acidez por ERGE no erosiva en adultos
- Sanación y mantenimiento de ERGE erosiva en adultos
- Tratamiento de la infección por H. pylori mediante VOQUEZNA® TRIPLE PAK® y VOQUEZNA® DUAL PAK®
Phathom Pharmaceuticals (NASDAQ: PHAT)는 2025년 1분기 재무 실적 발표 및 사업 업데이트를 2025년 5월 1일 목요일 오전 8시(EDT)에 예정하고 있습니다. 회사는 투자자 관계 웹사이트를 통해 실시간 웹캐스트를 진행하며, 녹화본은 이후 90일간 제공됩니다.
Phathom은 위장 질환 치료에 전문화되어 있으며 미국에서 VOQUEZNA®(vonoprazan) 정제를 판매하고 있습니다. 제품 라인업에는 다음과 같은 치료제가 포함됩니다:
- 성인의 비침식성 GERD 속쓰림 완화
- 성인의 침식성 GERD 치유 및 유지
- VOQUEZNA® TRIPLE PAK® 및 VOQUEZNA® DUAL PAK®를 통한 H. pylori 감염 치료
Phathom Pharmaceuticals (NASDAQ : PHAT) a programmé l'annonce des résultats financiers du premier trimestre 2025 ainsi qu'une mise à jour commerciale pour le jeudi 1er mai 2025 à 8h00 EDT. La société organisera une webdiffusion en direct accessible via son site web pour les investisseurs, avec un enregistrement disponible pendant 90 jours après la diffusion.
Phathom est spécialisée dans les traitements des maladies gastro-intestinales et commercialise aux États-Unis les comprimés VOQUEZNA® (vonoprazan). Leur gamme de produits comprend des traitements pour :
- Le soulagement des brûlures d’estomac dues au RGO non érosif chez l’adulte
- La guérison et le maintien du RGO érosif chez l’adulte
- Le traitement de l’infection à H. pylori via VOQUEZNA® TRIPLE PAK® et VOQUEZNA® DUAL PAK®
Phathom Pharmaceuticals (NASDAQ: PHAT) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate für Donnerstag, den 1. Mai 2025, um 8:00 Uhr EDT geplant. Das Unternehmen wird ein Live-Webcast über seine Investor-Relations-Website veranstalten, die Aufzeichnung ist anschließend 90 Tage lang verfügbar.
Phathom ist auf Behandlungen von Magen-Darm-Erkrankungen spezialisiert und vertreibt in den USA VOQUEZNA® (Vonoprazan) Tabletten. Das Produktportfolio umfasst Behandlungen für:
- Erwachsene mit nicht-erosiver GERD zur Linderung von Sodbrennen
- Heilung und Erhaltung der erosiven GERD bei Erwachsenen
- Behandlung von H.-pylori-Infektionen mit VOQUEZNA® TRIPLE PAK® und VOQUEZNA® DUAL PAK®
- None.
- None.
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT
FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When will Phathom Pharmaceuticals (PHAT) release Q1 2025 earnings?
How can investors access Phathom Pharmaceuticals' (PHAT) Q1 2025 earnings call?
What treatments does Phathom Pharmaceuticals (PHAT) currently market in the US?
What medical conditions does VOQUEZNA treat?
